

Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review

T Kimhofer^{1,4}, H Fye^{*,2,4}, S Taylor-Robinson³, M Thursz³ and E Holmes¹

¹Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, 661 Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, UK; ²MRC Unit (UK), The Gambia Laboratories, PO Box 273, Fajara, Atlantic Boulevard, The Gambia and ³Liver Unit, Division of Diabetes Endocrinology and Metabolism, Department of Medicine, Imperial College London, 10th Floor QEOM Building, St Mary's Hospital Campus, South Wharf Road, London W2 1NY, UK

Hepatocellular carcinoma (HCC) ranks third in overall global cancer-related mortality. Symptomatic presentation often means advanced disease where potentially curative treatment options become very limited. Numerous international guidelines propose the routine monitoring of those with the highest risk factors for the condition in order to diagnose potential tumourigenesis early. To aid this, the fields of metabonomic- and proteomic-based biomarker discovery have applied advanced tools to identify early changes in protein and metabolite expression in HCC patients vs controls. With robust validation, it is anticipated that from these candidates will rise a high-performance non-invasive test able to diagnose early HCC and related conditions. This review gathers the numerous markers proposed by studies using mass spectrometry and proton nuclear magnetic resonance spectroscopy and evaluates areas of consistency as well as discordance.

Hepatocellular carcinoma (HCC) ranks third in overall global cancer-related mortality (Ferlay *et al*, 2010) accounting for 85–90% of all tumours emerging from the liver in high-incidence areas and between 70 and 75% of cases in lower incidence regions. In a 2008 survey, overseen by the World Health Organisation (WHO), it was reported that there were ~748 000 new cases of liver cancer diagnosed worldwide, in that year alone, with an estimated 695 000 reported deaths in the same period (Ferlay *et al*, 2010). These figures reflect the high mortality rate of this disease owing to multiple contributing factors; most important of which include the absence of monitoring in high-risk populations, insufficient diagnostic resources, and very limited treatment options, many of which require early tumour identification for any potential of curative intervention. As a consequence, the HCC biomarker discovery field is rapidly expanding with new and ongoing research continuing to propose a fast growing list of biomarker candidates. Many of these candidate biomarkers await further validation before being used in conjunction with, or in place of ultrasound scanning as the primary non-invasive test for HCC determination.

The main risk and causative factors for HCC are well described in the literature with a distinct geographical separation observed between established infectious agents such as the hepatitis B and C viruses (HBV and HCV) vs an increasing number of lifestyle-related risk factors such as chronic alcohol abuse (Morgan *et al*, 2004) non-alcoholic steatohepatitis, diabetes and obesity (Regimbeau *et al*, 2004; El-Serag and Rudolph, 2007). The focus of this review is to summarise and explore the new potential candidate biomarkers arising from the surge of proteomic and metabolic profiling studies infiltrating the literature. The advance of these markers through the implementation of systems biology approaches will bring to the forefront robust candidates for enhanced diagnostics and therapies for chronic liver diseases (CLDs; Bertino *et al*, 2014; Malaguarnera *et al*, 2014). The key selection criteria for an ideal biomarker for any disease are for the:

- Target molecule to be measurable in a non-invasive sample source such as blood or urine.
- Marker to have excellent diagnostic and/or prognostic abilities for condition of interest (i.e., high sensitivity and specificity).

*Correspondence: Dr H Fye; E-mail: hfye@mrc.gm

⁴These authors contributed equally to this work.

Received 15 July 2014; revised 4 November 2014; accepted 20 December 2014

© 2015 Cancer Research UK. All rights reserved 0007–0920/15

- Marker should be amenable to measurement techniques that are reliable, robust, and reproducible and, for use in field analysis should ideally take a simple kit-based format not requiring additional equipment for interpretation.
- Assay should be cheap and thus accessible to all the populations requiring it.
- The biomarker should be validated across a broad range of populations.

Currently the most widely used biomarker for HCC, particularly in the developing world where disease burden is greatest is alpha-fetoprotein (AFP). Alpha-fetoprotein ticks several of the boxes in relation to the points mentioned above but fails dramatically in its diagnostic performance and ability, thus significantly reducing its reliability in clinical settings.

The role of AFP in diagnosing HCC and monitoring those at high risk of its development is heavily constrained, with revised guidelines reflecting its significant limitations in this regard. A publication by the American Association for the Study of Liver Diseases (AASLD) summarises that AFP 'lacks adequate sensitivity and specificity for effective surveillance and for diagnosis' of HCC (Bruix and Sherman, 2011). Similarly, the European Association for the Study of the Liver (EASL) does not recommend AFP within the panel of tests for HCC diagnosis (European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, 2012). Not much has been reported on the independent diagnostic ability of AFP, but it is approximated at 0.70, with at least one publication showing area under the curve (AUC) values as low as <0.60 when used at a cut-off of 100 ng ml^{-1} (Giannini *et al*, 2012). To circumvent this problem, advanced radiological methods are increasingly being relied on as the best non-invasive tools for accurate diagnosis and monitoring of CLD patients. However, as CLDs and their sequelae of conditions inflict their biggest burden in the developing world, this shift has meant that many of the patients mostly in need of monitoring and diagnosis are left to rely on the poor performance of AFP. The AASLD and EASL both recommend routine surveillance of patients with chronic hepatitis infections and fibrosis, to detect HCC at the early disease stage, when curative treatment options such as tumour resection (Bruix and Sherman, 2011), ablation (Livraghi *et al*, 2008), transarterial chemoembolisation (Llovet and Bruix, 2003), and liver transplant, recommended for patients with localised tumours on a background of advanced cirrhosis are still prospective. To make this a reality, there is an urgent need for the identification and conversion into clinical use of affordable, non-invasive, and high-performance diagnostic tools deployable in both the developing and developed worlds.

With the availability of novel state-of-the-art technologies and approaches, medical researchers have in recent years used the tools of mass spectrometry (MS) and proton nuclear magnetic resonance (^1H NMR) spectroscopy to delve deeper into the human proteome and metabolome from accessible body fluids in order to identify high-performance screening and diagnostic markers capable of detecting and or predicting HCC development. However, there are currently no clinically approved alternatives to AFP that could form robust, non-invasive routine tests available to confidently detect HCC or its main precursor condition of liver cirrhosis (LC) at their early stages. This review aims to summarise and assess literature reports of the application of ^1H NMR spectroscopy and MS methods to identify and validate the differential expression of proteins, and metabolites potentially exploitable as biomarkers of HCC. Some degree of focus will be given to markers of earlier stages of CLD such as liver fibrosis and LC where they have been reported. However, due to the high degree of variability in research approaches used to validate the expression trends of putative biomarkers and the small sample sizes generally utilised in profiling, a true meta-analysis of all published work is as yet not

possible. Part of the selection criteria for inclusion of papers in this review was that all initial discovery of proposed markers was to be conducted using spectroscopic methodologies, it may thus be striking that some of the more widely proposed markers associated with HCC and CLDs are absent. These have mainly been proposed in experiments utilising more classical protein and metabolite identification and measurement methods, and thus do not form the focus of this work. Many of these classical markers have been widely discussed and reviewed in the context of liver diseases (Bertino *et al*, 2012; Masuzaki *et al*, 2012). Several worthy of mention include des-carboxy prothrombin, squamous cell carcinoma antigen-immunoglobulin M complexes, and chromogranin A, which have been proposed and/or compared with AFP in key publications (Bertino *et al*, 2010, 2011; Biondi *et al*, 2012). As the list of candidate markers being identified and proposed by spectroscopic methods increases, it is important that reports are comprehensively amalgamated in order to allow researchers to focus more on validating their robustness and expression patterns using independent methods and platforms. This review is an attempt to accelerate this agenda and to ascertain which panel of metabolites and proteins would offer a parsimonious and robust solution for an effective diagnosis.

MATERIALS AND METHODS

This review focuses on biomarkers proposed from sources searched in the databases PubMed and Google Scholar. The exact search procedure is outlined in Figure 1. For the identification of proteomic papers, the PubMed database was searched with the term '(((Hepatocellular Carcinoma) AND Biomarker) AND Proteomics)'. For the metabolomics part, a similar PubMed search was conducted (but with the word 'metabonomics' instead of 'proteomics'). All returned publications shortlisted for




Figure 1. The search terms 'Proteomics' or 'Metabonomics' and 'Hepatocellular Carcinoma' and 'Biomarker' were entered into the search engine PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>). For the identification of metabolomic publications, an additional Google Scholar search was conducted for the time range 2003–2013 (<http://scholar.google.co.uk/>).

adherence to the inclusion/exclusion criteria stated below were considered for analyses. Since only 10 metabolomic publications were identified on PubMed, an additional Google Scholar search was conducted, which identified a further eight publications. Additional publications were identified by screening all references associated with these primary papers.

The criteria for inclusion in this review were:

- HCC biomarker studies using plasma, serum, or (for metabolomic papers) urine.
- HCCs linked to established viral and dietary risk factors with no reports of metastases.
- Initial discovery conducted on a MS or ^1H NMR spectroscopy-based platform.

Exclusion criteria were non-English literature reports, studies on tissues, cell lines, or animals. Studies including subjects who underwent surgery or transplant were also excluded in order to avoid cases of recurrent HCC following treatment or intervention – these recurrences may have unique developmental profiles that could influence scope of targets identified. Once this initial filtering was applied, a secondary criterion including biomarker candidates with multiple reports, that is, the biomarker should have been reported by at least two independent methods or research groups, was applied.

HCC markers proposed by metabolomic studies. The liver is the metabolic hub of humans as most compounds absorbed by the intestine pass through it at least once. Owing to this, it is able to regulate the expression levels of numerous metabolites, which makes metabolomic analyses approaches particularly relevant for the investigation of liver diseases, such as LC and HCC. In recent years, a lot of effort has been put into metabolomic research on CLDs mainly using urine, blood, or hepatic tissue sections. A number of differential metabolites have been reported by the few studies on HCC tumour tissues, suggesting that there are major metabolic changes taking place during disease development and progression. A common finding of these studies is a glycolytic HCC phenotype (Yang *et al*, 2007b; Beyoğlu *et al*, 2013), indicating that the Warburg effect may take place in liver cancer. Although this and other findings give important insight into HCC tumour biology from a clinical perspective, a more important question is whether there exist specific metabolites detectable in biofluids, such as blood or urine, which can serve as biomarkers for the diagnosis of early HCC.

Up to the submission of this review, 22 metabolomic studies matched the inclusion criteria described above and investigated the blood and/or urine metabolome in the context of HCC (Table 1). Most of these studies are MS based and investigate HCC in the context of HBV or HCV (Table 2), which reflects the global trend of primary HCC risk factors (Boyle and Levin, 2008). In contrast, the patient cohorts' ethnicities in these studies did not reflect the geographical distribution of HCC incidence. Although the majority of studies were performed in China, where HCC is a major health

issue, only a single study investigated the metabolome of HCC in a sub-Saharan African cohort (Table 2), where HCC is an equally important health burden (Ferlay *et al*, 2010).

Most studies inferred differential expression of metabolites by comparing either serum or urine profiles of HCC patients with control groups, mainly made up of healthy volunteers or cirrhotics. This was accomplished with univariate and/or multivariate statistical methods. Multivariate methods used in these publications not only include partial least squares discriminant analysis (PLS-DA), but also support vector machine and random forest approaches. On average 18 biomarker candidates were identified per study, with only 32% of these using established diagnostic models for comprehensive assessment of diagnostic performance. This low assessment rate makes a meta-analysis impossible at this stage.

The following section is structured according to compound classes to provide an overview of the metabolites that were reported in more than one study. In addition, the diagnostic models that have been reported to perform extremely well in diagnosing HCC will be mentioned at the end of this section.

Bile acids. Bile acids constitute one of the most frequently reported compound classes suggested as discriminating between HCC patients and a control group, be it healthy or CLD. An increase in conjugated bile acids has long been recognised in patients with hepatobiliary diseases in general, such as viral hepatitis, cirrhosis, HCC, and cholangiocarcinoma (Neale *et al*, 1971). Many metabolomic publications reviewed here confirm an increase in particular conjugated serum bile acids in HCC patients when compared to healthy individuals (Table 3).

Interestingly, higher bile acid serum levels (glycochenodeoxycholic acid, glycocholic acid, CA, and deoxycholic acid (DCA)) have been found in HCC patients with cirrhosis, than without (Chen *et al*, 2011b), which may indicate that the bile acid concentration is primarily associated with cirrhosis or overall hepatic performance. Evidence for this is given by Chen *et al*, 2012, who found serum bile acids increased in patients with hepatic decompensation, when compared to compensated patients. A closer look at the HCC cohorts' characteristics of the matched studies reveals that only a few assessed and included the extent of liver disease in the background of HCC or the hepatic compensation/decompensation status in their analyses (Table 2). This may have significantly biased the results. Other confounding factors that have not been controlled for many studies include (1) the prandial state of the patients (elevated serum levels of certain bile acids have been reported previously in patients after food intake (LaRusso *et al*, 1978; Ponz De Leon *et al*, 1978)) and (2) the size of the tumour mass. Large tumour masses may compromise the ability of non-tumourous liver tissue to produce bile acids, thereby lowering the serum bile acid levels. Although some studies report the fraction of HCC patients in different tumour stages, the majority of studies did not include that information in their data analyses.

Altogether, the level of serum bile acids reported here seems to be associated primarily with cirrhosis and not HCC and we do not recommend this compound group as biomarkers for early HCC without further directed analysis of the bile acids across different stages of cirrhosis. From a mechanistically viewpoint, bile acids may play a role in the development of HCC, for example, by the production reactive oxygen species, thereby producing oxidative stress and DNA damage (Baptissart *et al*, 2013). Some of the bile acids have also been described as versatile signalling molecules (Thomas *et al*, 2008, 2009; Gadaleta *et al*, 2011), for instance, lithocholic acid and DCA are both involved in the promotion of energy expenditure and participation in glucidic metabolism by acting on the G-protein-coupled receptor TRG5 (Baptissart *et al*, 2013).

Table 1. Number of metabolomic publications broken down to platform and specimen type

Biofluid	^1H NMR	MS	Total
Urine	2	3 (1 ^a)	5
Serum/plasma	3	13 (4 ^a)	16
Both	—	1	1
Total	5	17	22

Abbreviations: ^1H NMR = proton nuclear magnetic resonance; MS = mass spectrometry.
^aNumber of studies that included a validation cohort.

Table 2. Summary of metabonomic studies that were reviewed

Reference	Biofluid	Platform	Cohort sizes	Validation cohort	Aetiology	Sex (m:f)	HCC group		
							Background CLD	Ethnicity	Staging
Baniasadi <i>et al</i> , 2013	Serum	HPLC-MS/MS (MRM)	HCC: 30 CIR: 22	No	HCV	3.3:1	Yes	Mainly Caucasian	No
Chen <i>et al</i> , 2011a	Serum	UPLC-MS/MS	HCC: 41 HCON: 38	No	HBV	2:1	No information	Chinese	No
Chen <i>et al</i> , 2013b	Serum	UFLC-IT-TOF/MS	HCC: 30 CIR: 30 CHB: 30 HCON: 30	No	HBV	No information	No information	Chinese	No
Chen <i>et al</i> , 2013a	Serum	UHPLC-TQ-MS (MRM)	HCC: 29 HCON: 30	No	No information	No information	No information	No information	No
Chen <i>et al</i> , 2011b	Serum, urine	GC-TOF-MS, UPLC-qTOF-MS	HCC: 82 Benign LD: 24 HCON: 71	Yes	Mainly HBV	2:1	Majority yes	Chinese	TMN
Chen <i>et al</i> , 2009	Urine	RPLC-qTOF-MS, HILIC-qTOF-MS	HCC: 21 HCON: 24	Yes	No information	Partially	No information	Chinese	No
Gao <i>et al</i> , 2009	Serum	¹ H NMR	HCC: 39 CIR: 36 HCON: 63	No	HCC: HCV CIR: No information	No information	No information	Chinese	No
Huang <i>et al</i> , 2013	Serum	UHPLC-MS CE-MS	HCC: 139 CIR: 78 CHB: 81	Yes	HCC: Mainly HBV CIR: HBV	5.3:1	No information	No information	No
Nahon <i>et al</i> , 2012a	Serum	¹ H NMR	HCC: 61 CIR: 93	Yes	Alcohol	1:0	Yes	Caucasian or residence in France	Small HCC Large HCC
Patterson <i>et al</i> , 2011	Plasma	UPLC-qTOF-MS UPLC-TQ-MS (MRM) GC-MS	HCC: 20 CIR: 7 AML: 22 HCON: 6	No	HCC: Mixed CIR: No information	5.6:1	Majority yes	No information	Barcelona criterion
Ressom <i>et al</i> , 2012	Serum	UPLC-qTOF-MS, UPLC-MS (SRM)	HCC: 78 CIR: 184	No	HCC: Mainly HCV CIR: Mixed	5.5:1	Yes	Mainly Caucasian	Yes (system not specified)
Shariff <i>et al</i> , 2011	Urine	¹ H NMR	HCC: 16 CIR: 14 HCON: 17	No	Mainly HCV	15:1	Majority yes	Egyptian	Okuda
Shariff <i>et al</i> , 2010	Urine	¹ H NMR	HCC: 18 CIR: 10 HCON: 14	No	HCC: Mainly HBV CIR: HBV	2:1	No information	Nigerian	Okuda
Wang <i>et al</i> , 2012	Serum	UPLC-MS	HCC: 23 CIR: 28 HCON: 70	Yes	HBV	12:1	Partially	Chinese	AJCC
Wei <i>et al</i> , 2012	Serum	¹ H NMR	HCC: 40 CHC: 22	No	HCV	3.3:1	No information	Mainly Caucasian	No
Wu <i>et al</i> , 2009	Urine	GC-MS	HCC: 20 HCON: 20	No	No information	1:0	No information	Chinese	No
Xiao <i>et al</i> , 2012	Serum	UPLC-qTOF-MS UPLC-MS/MS (SRM)	HCC: 40 CIR: 49	No	HCC: HCV CIR: Mainly HCV	3.4:1	No information	Egyptian	TMN
Xue <i>et al</i> , 2008	Serum	GC-MS	HCC: 20 HCON: 20	No	No information	1:0	No information	Chinese	No
Yin <i>et al</i> , 2009	Serum	RPLC-qTOF-MS, HILIC-qTOF-MS	HCC: 24 CIR: 25 HCON: 25	No	HCC: No information CIR: HBV	No information	Partially	Chinese	No
Zhang <i>et al</i> , 2013	Urine	UPLC-qTOF-HDMS	HCC: 25 HCON: 12	No	No information	1:1	No information	Chinese	No
Zhou <i>et al</i> , 2012a	Serum	UPLC-qTOF-MS (MRM)	HCC: 69 CIR: 28 HCON: 31	No	HBV and HCV	4.3:1	No information	Chinese	No
Zhou <i>et al</i> , 2012b	Serum	RPLC-qTOF-MS	HCC: 30 CIR: 30 CHB: 30 HCON: 30	No	No information	2.3:1	Yes	Chinese	No

Abbreviations: AJCC = American Joint Committee on Cancer; AML = acute myeloid leukaemia; CE = capillary electrophoresis; CHB = chronic hepatitis B; CHC = Carcinome HepatoCellulaire; CIR = cirrhosis cohort; CLD = chronic liver disease; GC = gas chromatography; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCON = healthy control cohort; HCV = hepatitis C virus; HDMS = high-definition mass spectrometry; HILIC = hydrophobic interaction chromatography; IT = ion trap; MRM = multiple reaction monitoring; MS = mass spectrometry; NMR = nuclear magnetic resonance; qTOF = quadrupole time of flight; RPLC = reversed phase liquid chromatography; SRM = single reaction monitoring; TOF = time of flight; TQ = triple quadrupole; UFLC = ultra-fast liquid chromatography; UHPLC = ultra-high-performance liquid chromatography; UPLC = ultra-performance liquid chromatography.

Conflicting urinary concentrations of free glycine and taurine, two bile acid conjugates, have also been reported. These equivocal reports may also be explained by the recruitment of heterogeneous study cohorts (which differ in the degree of background liver disease or tumour masses). Since, both of the amino acids, glycine and taurine exhibit a wide range of metabolic activity, it is likely that their serum and urine concentrations in HCC patients reflect multiple metabolic processes, which further complicates the interpretation of these results. Less frequently reported bile compounds include various other bile acid species.

Lysophosphatidylcholines. When compared to a healthy control group, nine lysophosphatidylcholines (LPCs) have been reported to be significantly decreased in the sera of HCC patients in multiple publications (Table 4). The most frequently reported species include LPC C16:0, LPC C18:0, and LPC C18:2. Two of these (LPC 16:0 and LPC 18:0) have also been reported to be differentially expressed in the sera of HCC patients when compared with cirrhotic patients, with increased serum levels of LPC C18:0 and inconclusive findings for LPC C16:0. The depletion of LPC C16:0 in HCC tumours has recently been

described by two independent tissue metabolomic studies (Beyoglu *et al*, 2013; Huang *et al*, 2013). Transcriptomic analyses confirmed the overexpression of lysophosphatidylcholine acyltransferase 1 (LPCAT1), which converts LPC C16:0 to phosphatidylcholine 18:1 (Morita *et al*, 2013). This upregulation of LPCAT1 could account for the depletion of LPC C16:0. However, some LPC species, including 16:0, LPC 18:0, LPC 20:4, and LPC 20:5 have also been described as differentially expressed between hepatic decompensated and compensated patients (Chen *et al*, 2012). As mentioned before, many studies did not control for the background liver disease, that is, hepatic performance, which could have biased the described findings.

LPCs, together with arachidonic acid, may play important roles in the progression of HCC, as they have been described as important players in endothelial cell migration, that is, vascularisation processes (Linkous *et al*, 2010). This finding matches with the observation that hypervascularisation is a frequent feature of HCC. A positive relationship has been described between LPC concentrations and both body weight and inflammatory processes in malignant diseases (Taylor *et al*, 2007). The detection of urinary LPCs in the context of HCC has not been reported.

Table 3. Bile acid compounds discriminatory between HCC and comparison group

Compound	HMDB ID	Association	HCC: Healthy		HCC: Cirrhosis	
			Serum	Urine	Serum	Urine
GCA	00138	Bile acid	↑ (Yin <i>et al</i> , 2009; Chen <i>et al</i> , 2011b; Zhou <i>et al</i> , 2012a, b)	↑ (Chen <i>et al</i> , 2011b; Zhang <i>et al</i> , 2013)	↓ (Ressom <i>et al</i> , 2012; Xiao <i>et al</i> , 2012)	
GCDCA	00637	Bile acid	↑ (Yin <i>et al</i> , 2009; Chen <i>et al</i> , 2011b; Wang <i>et al</i> , 2012; Zhou <i>et al</i> , 2012b) [†]		↓ (Wang <i>et al</i> , 2012; Xiao <i>et al</i> , 2012)	
GDCA	00631	Bile acid	↑ (Patterson <i>et al</i> , 2011; Zhou <i>et al</i> , 2012a)		↓ (Ressom <i>et al</i> , 2012; Xiao <i>et al</i> , 2012)	
TCA	00036	Bile acid	↑ (Yin <i>et al</i> , 2009; Chen <i>et al</i> , 2011b) [†]			
TCDC	00951	Bile acid			↓ (Ressom <i>et al</i> , 2012; Xiao <i>et al</i> , 2012)	
Glycine	00123	Bile acid conjugate		↓ (Shariff <i>et al</i> , 2011) ↑ (Wu <i>et al</i> , 2009)		
Taurine	00251	Bile acid conjugate	↓ (Yin <i>et al</i> , 2009) ↑ (Chen <i>et al</i> , 2011b)			

Abbreviations: GCA = glycocholic acid; GCDCA = glycochenodeoxycholic acid; GDCA = glycodeoxycholic acid; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HMDB = The Human Metabolome Database; TCA = taurocholic acid; TCDC = taurochenodeoxycholic acid. ↓ indicates decrease in HCC; ↑ indicates increase in HCC; † indicates control group of the study (Yin *et al*, 2009) comprised chronic HCV carriers.

Table 4. LPCs reported to be discriminatory between HCC and comparison groups

Compound	HMDB ID	Association	HCC: Healthy		HCC: Cirrhosis	
			Serum	Urine	Serum	Urine
LPC C14:0	10379	Phospholipid catabolism	↓ (Patterson <i>et al</i> , 2011; Zhou <i>et al</i> , 2012b; Chen <i>et al</i> , 2013a)			
LPC C16:0	10382	Phospholipid catabolism	↓ (Patterson <i>et al</i> , 2011; Wang <i>et al</i> , 2012; Zhou <i>et al</i> , 2012a; Chen <i>et al</i> , 2013a, b)		↓ (Patterson <i>et al</i> , 2011; Zhou <i>et al</i> , 2012a) ↑ (Ressom <i>et al</i> , 2012; Wang <i>et al</i> , 2012)	
LPC C18:0	10384	Phospholipid catabolism	↓ (Yin <i>et al</i> , 2009; Patterson <i>et al</i> , 2011; Wang <i>et al</i> , 2012; Zhou <i>et al</i> , 2012a;)		↑ (Ressom <i>et al</i> , 2012; Wang <i>et al</i> , 2012)	
LPC C18:1	02815/10385/10408	Phospholipid catabolism	↓ (Patterson <i>et al</i> , 2011; Zhou <i>et al</i> , 2012a; Chen <i>et al</i> , 2013a)			
LPC C18:2	10386	Phospholipid catabolism	↓ (Yin <i>et al</i> , 2009; Zhou <i>et al</i> , 2012a; Baniasadi <i>et al</i> , 2013; Chen <i>et al</i> , 2013a, b)			
LPC C18:3	10386	Phospholipid catabolism	↓ (Yin <i>et al</i> , 2009; Patterson <i>et al</i> , 2011)			
LPC C20:3	10393/10394	Phospholipid catabolism	↓ (Patterson <i>et al</i> , 2011; Zhou <i>et al</i> , 2012b)			
LPC C20:4	10395/10396	Phospholipid catabolism	↓ (Patterson <i>et al</i> , 2011; Zhou <i>et al</i> , 2012a)			
LPC C20:5	10397	Phospholipid catabolism	↓ (Patterson <i>et al</i> , 2011; Zhou <i>et al</i> , 2012b)			

Abbreviations: HCC = hepatocellular carcinoma; HMDB = The Human Metabolome Database; LPCs = lysophosphatidylcholines. ↓ indicates decrease in HCC; ↑ indicates increase in HCC.

Free fatty acids. Although numerous free fatty acid (FFA) species have been described as being discriminatory in serum between HCC patients and a control group, there was no common trend in serum FFA levels observable with some studies reporting increased levels and others reporting a decrease in FFA concentrations (Table 5). FFA species reported frequently include FFA C16:0, FFA C18:0, FFA C20:4, and FFA C24:1. The conflicting reports on the serum concentrations may be a result of heterogenic patient groups, in terms of different diets, gender, comorbidities (such as cardiovascular diseases), and of course the extent of liver damage, that is the hepatic compensation/decompensation status. As was the case for bile acids and LPCs, FFA levels seem to be also influenced by background liver disease (Chen *et al*, 2012). The association of FFA 16:0 and FFA 18:0 with hepatitis B and cirrhosis has been described by Chen *et al*, 2011b, who investigated HCC patients with and without LC and hepatitis separately. In contrast, increased concentrations of FFA C16:0 and FFA C18:0 have been confirmed by a tissue metabolomic study on HCC (Huang *et al*, 2013), indicating that there may be quantitative differences between serum FFA concentrations of HCC and cirrhosis patients.

Other serum lipid compounds found to be discriminative between HCC and healthy controls are FFA C24:1 and oleamide. Although FFA 24:1 has not been found to discriminate between cirrhosis and HCC patients, oleamide has. Oleamide, the amide of FFA C18:1 (oleic acid), exhibits a variety of neuropharmacological effects, including increased food intake (Martínez-González *et al*, 2004) and relaxation of blood vessels (Hoi and Hiley, 2006). Since Oleamide has not been associated with CLDs, nor previously been reported in cancer literature, it may represent a specific marker for HCC. However, further validation studies are required.

Carnitine and related acylesters. A compound class closely associated to fatty acids and their catabolism, is carnitine and its acylesters. Carnitine is mainly derived from dietary sources and its main function is to transport activated long-chain fatty acids from the cytosol into the mitochondria for energy production via beta-oxidation. Physiologically, almost all free carnitine is intracellular (Cave *et al*, 2008) and the renal absorption rate is high (Bellinghieri *et al*, 2003). Interestingly, two urinary NMR studies report a trend towards increased urinary levels of free carnitine HCC patients, when compared with a healthy control or cirrhosis group (Table 6). Since renal function was not assessed in any of the studies considered in this review, and renal diseases, such as the hepatorenal syndrome, are common secondary to cirrhosis and HCC, increased urinary-free carnitine may indicate kidney dysfunction, instead of being specific for HCC. Increased urinary acylcarnitines (esterified acyl groups with carnitine) have been

reported in specific FFA oxidation disturbances and after extensive workout (Flanagan *et al*, 2010). Urinary acetylcarnitine, however, has not been associated with HCC before and may therefore be a specific HCC biomarker candidate.

The differential serum levels of carnitines, when HCC is compared to a healthy control cohort, seem to exhibit a specific pattern, with mostly increased free carnitine levels, decreased short to medium-chain acylcarnitines and increased levels of long-chain acylcarnitine C18:1 and C18:2. A major role of short- and medium-chain acylcarnitines is to remove organic acids from organelles such as mitochondria, and eventual excretion in urine and bile. The decrease in serum, however, indicates either an increased excretion rate or a decreased accumulation rate. In contrast, long-chain acylcarnitines are formed intracellularly for the purpose of energy production. Therefore, elevated long-chain acylcarnitine levels could possibly permit an increased FFA transport into mitochondria and hence increase energy production.

The interpretation of these findings should be taken with caution, since carnitine levels can be influenced by many other factors, such as by diet, renal dysfunction or altered biosynthesis rates. Blood acylcarnitines levels may also be influenced by the hepatic fatty acid metabolism, that is, increased (or decreased) acylcarnitine levels due to the increased (or decreased) production of acyl groups in the liver or other tissues.

There is a body of evidence that patients with different cirrhosis aetiologies show specific carnitine profiles. For instance, when compared to healthy volunteers, patients with viral hepatitis-induced cirrhosis (HBV and HCV) showed an increase in plasma long-chain acylcarnitines, whereas patients with alcohol-induced cirrhosis had elevated levels of both, long- and short-chain acylcarnitines (Krähenbühl, 1996). Clinical studies on L-carnitine and acetyl-L-carnitine as a dietary supplement found positive effects on cognitive function (Malaguarnera, 2012), indicating that treatment with carnitine may provide useful information on energy metabolism in cirrhosis and HCC.

Increased urinary and plasma carnitine and acylcarnitine levels have also been described in kidney diseases (Calabrese *et al*, 2006; Ganti *et al*, 2012) and in patients treated with certain chemotherapeutic drugs, such as cisplatin (Dodson *et al*, 1989; Heuberger *et al*, 1998).

Energy, nucleotide, and amino acid metabolism. Other energy metabolism-related compounds found to be discriminatory between HCC and healthy cohorts include 2-oxoglutarate, succinate, and glycerol (Table 7). The elevation of 2-oxoglutarate, a key component of the TCA cycle, may be a consequence from a decreased mitochondrial respiration, that is, the Warburg effect. This hypothesis is strengthened by tissue metabolomics studies

Table 5. Discriminative FFAs between HCC and comparison groups

Compound	HMDB ID	Association	HCC: Healthy		HCC: Cirrhosis	
			Serum	Urine	Serum	Urine
FFA C24:1 (nervonic acid)	02368	Lipid metabolism/energy metabolism	↓ (Chen <i>et al</i> , 2011b; Patterson <i>et al</i> , 2011)			
Oleamide	02117	Lipid metabolism/energy metabolism	↓ (Chen <i>et al</i> , 2011b) ↑ (Wang <i>et al</i> , 2012)		↓ (Wang <i>et al</i> , 2012; Xiao <i>et al</i> , 2012)	
FFA C16:0 (palmitic acid)	00220	Lipid metabolism/energy metabolism	↓ (Chen <i>et al</i> , 2011b) ↑ (Zhou <i>et al</i> , 2012b) • (Xue <i>et al</i> , 2008)			
FFA C18:0 (stearic acid)	00827	Lipid metabolism/energy metabolism	↓ (Chen <i>et al</i> , 2011b) ↑ (Zhou <i>et al</i> , 2012b) • (Xue <i>et al</i> , 2008)			
FFA C20:4 (arachidonic acid)	01043	Lipid metabolism/energy metabolism	↓ (Chen <i>et al</i> , 2011b) ↑ (Zhou <i>et al</i> , 2012a, Zhou <i>et al</i> , 2012b)			

Abbreviations: FFAs = free fatty acids; HCC = hepatocellular carcinoma; HMDB = The Human Metabolome Database. ↓ indicates decrease in HCC; ↑ indicates increase in HCC; • indicates not reported whether decreased or increased.

Table 6. Discriminative carnitines between HCC and comparison groups

Compound	HMDB ID	Association	HCC: Healthy		HCC: Cirrhosis	
			Serum	Urine	Serum	Urine
Carnitine	00062	Energy metabolism	↑ (Yin <i>et al</i> , 2009; Chen <i>et al</i> , 2011b) ↓ (Zhou <i>et al</i> , 2012b; Huang <i>et al</i> , 2013)	↑ (Chen <i>et al</i> , 2009; Shariff <i>et al</i> , 2010, 2011)		↑ (Shariff <i>et al</i> , 2010, 2011)
Acetylcarnitine	00201	Energy metabolism	↑ (Yin <i>et al</i> , 2009) ↓ (Zhou <i>et al</i> , 2012b)			
Acylcarnitine C3:0	00824	Energy metabolism	↓ (Zhou <i>et al</i> , 2012b; Huang <i>et al</i> , 2013)			
Acylcarnitine C8:0	00791	Energy metabolism	↓ (Zhou <i>et al</i> , 2012b; Chen <i>et al</i> , 2013a)			
Acylcarnitine C8:1	00791	Energy metabolism	↓ (Zhou <i>et al</i> , 2012b; Chen <i>et al</i> , 2013a)			
Acylcarnitine C10:0	00651	Energy metabolism	↓ (Zhou <i>et al</i> , 2012b; Chen <i>et al</i> , 2013a)			
Acylcarnitine C10:1	13205	Energy metabolism	↓ (Zhou <i>et al</i> , 2012b; Chen <i>et al</i> , 2013a)			
Acylcarnitine C18:1	13338	Energy metabolism	↑ (Zhou <i>et al</i> , 2012a, b; Chen <i>et al</i> , 2013a)		↓ (Xiao <i>et al</i> , 2012) ↑ (Zhou <i>et al</i> , 2012a)	
Acylcarnitine C18:2	13212	Energy metabolism	↑ (Zhou <i>et al</i> , 2012a, b; Chen <i>et al</i> , 2013a)		↓ (Xiao <i>et al</i> , 2012; Zhou <i>et al</i> , 2012a)	

Abbreviation: HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HMDB = The Human Metabolome Database. ↓ indicates decrease in HCC; ↑ indicates increase in HCC; † indicates control group of the study (Huang *et al*, 2013) comprised chronic HBV carriers.

that report glycolytic phenotypes of HCC (Huang *et al*, 2013). Contradictory urinary concentrations were reported for succinate, another TCA intermediate. A factor that may convolve the biological signal in urinary metabolite profiles is the extent of which a urinary metabolite concentration reflects the metabolite's blood concentration. Although the urinary metabolome is a subset of the total body metabolome, urinary metabolite concentrations depend on the renal excretion rate, which is metabolite specific and tightly regulated, depending on many factors such as blood pH. Evidence that supports this hypothesis is given in Chen *et al*, 2011b and Bouatra *et al*, 2013. Furthermore, a number of amino acids were found to discriminate between HCC and healthy controls in serum and/or urine. An amino acid imbalance has been recognised previously in the serum of patients with CLD; specifically the decrease in branched chain amino acids (BCAAs: leucine, isoleucine, and valine) and the increase in aromatic amino acids (AAAs: phenylalanine, tryptophan, tyrosine, and histidine); in particular tyrosine (Michitaka *et al*, 2010). This mainly has been supported by a metabolomic study, with an exception of phenylalanine, which was found increased in the sera of HCC patients, when compared to healthy controls. Decreased serum BCAAs may also be linked to elevated serum carnitine levels, since they are able to oxidise BCAAs (Hoppel, 2003).

In addition, the urinary concentration of the purine nucleoside hypoxanthine has been found to be significantly higher in HCC when compared to healthy individuals. However, another study reports a decreased urine concentration, potentially due to the different HCC aetiologies of the cohorts. A tissue metabolomic study reported increased hypoxanthine concentrations in HCC tissue, compared to matched non-tumourous tissue of HCC patients (Huang *et al*, 2013).

Other relevant metabolites, shown to be reduced in the urine of HCC patients, include creatinine and trimethylamine-*N*-oxide (TMAO). Urinary creatinine excretion is related to muscle mass (Oterdoom *et al*, 2009) and therefore may be a manifestation of cancer cachexia, instead of being specifically HCC related. Trimethylamine-*N*-oxide is generated in the liver from oxidation of the gut microbiota co-metabolite trimethylamine (TMA) by

flavin monooxygenases. The production of TMA by the human gut microbiota may represent a link between HCC and interactions of host – gut microbiota, which have previously been suggested to have the capacity to promote hepatocarcinogenesis (Mederacke *et al*, 2012). In addition, increased TMAO levels may be partially responsible for decrease of serum bile acids, since TMAO is involved in cholesterol metabolism (Koeth *et al*, 2013).

Diagnostic performance of metabolite biomarker candidates.

From 22 studies reviewed, only 6 assessed the diagnostic performance of the biomarker candidates proposed (Xue *et al*, 2008; Chen *et al*, 2011a; Wang *et al*, 2012; Zhou *et al*, 2012a; Baniyadi *et al*, 2013; Huang *et al*, 2013). However, the performance of these metabolomic models to detect and differentiate HCC from healthy volunteers or cirrhosis patients is consistently better than the performance of AFP. The model with the best performance in discriminating HCC from cirrhosis cohort was constructed with full-serum LC-MS data (without variable selection), yielding 100% sensitivity and specificity (ROC = 100%; Wang *et al*, 2012). A heavily reduced model, constructed with only canavaninosuccinate and AFP, achieved a sensitivity and specificity of 96.4 and 100%, respectively (Wang *et al*, 2012). Another high-performance model for the discrimination between HCC and cirrhosis patients was obtained with acetylcarnitine C3 (propionylcarnitine) and betaine, yielding in an AUC of 0.98 (Huang *et al*, 2013). A comparably high ROC value was obtained for a four-compound PLS-DA model for the discrimination between HCV infected cirrhosis patients with and without HCC, including methionine, 5-hydroxymethyl-2'-deoxyuridine, N2,N2-dimethylguanosine and uric acid (Baniyadi *et al*, 2013). The best model performance for the discrimination between HCC and healthy controls was based on serum levels of 1-methyladenosine combined with AFP, yielding in an AUC of 0.95 (Chen *et al*, 2011a). Very similar, in terms of performance, but without AFP was a model that included endocannabinoids anandamide and palmitylethanolamide yielding in an AUC of 0.94 (Zhou *et al*, 2012a). The same model was used to discriminate between HCC and cirrhotics with an AUC of 0.88. A different model that

Table 7. Additional metabolites associated with TCA cycle, and protein and nucleotide metabolism

Compound	HMDB ID	Association/ compound class	HCC: Healthy		HCC: Cirrhosis	
			Serum	Urine	Serum	Urine
Isoleucine	00687	AA/protein synthesis	↓ (Chen <i>et al</i> , 2013a) • (Xue <i>et al</i> , 2008)			
Leucine	00687	AA/protein synthesis	↓ (Chen <i>et al</i> , 2011b, 2013a)			
Methionine	00696	AA/protein synthesis	↓ (Chen <i>et al</i> , 2011b; Huang <i>et al</i> , 2013) †) ↑ (Chen <i>et al</i> , 2013a)			
Phenylalanine	00159	AA/protein synthesis	↓ (Chen <i>et al</i> , 2011b) ↑ (Gao <i>et al</i> , 2009; Wang <i>et al</i> , 2012; Zhou <i>et al</i> , 2012a; Chen <i>et al</i> , 2013a)		↓ (Wang <i>et al</i> , 2012; Zhou <i>et al</i> , 2012a; Baniasadi <i>et al</i> , 2013)	
Threonine	00167	AA/protein synthesis		↑ (Wu <i>et al</i> , 2009; Chen <i>et al</i> , 2011b)		
Tryptophan	00929	AA/protein synthesis	↓ (Chen <i>et al</i> , 2011b, 2013a; Zhou <i>et al</i> , 2012a, b)			
Tyrosine	00158	AA/protein synthesis	↑ (Gao <i>et al</i> , 2009; Chen <i>et al</i> , 2013a) ↓ (Chen <i>et al</i> , 2011b)	↑ (Wu <i>et al</i> , 2009; Chen <i>et al</i> , 2011b)		
Valine	00883	AA/protein synthesis	↓ (Gao <i>et al</i> , 2009; Chen <i>et al</i> , 2013a) ↑ (Wei <i>et al</i> , 2012) †			
Creatinine	00562	Alanine and proline metabolism	↓ (Chen <i>et al</i> , 2011b; Wei <i>et al</i> , 2012) †	↓ (Chen <i>et al</i> , 2009; Shariff <i>et al</i> , 2010, 2011)		↑ (Shariff <i>et al</i> , 2010, 2011)
Choline	00097	Lipid metabolism	↑ (Wei <i>et al</i> , 2012) †) ↓ (Gao <i>et al</i> , 2009)			
Glycerol	00131	Lipid metabolism/ energy metabolism	↓ (Chen <i>et al</i> , 2011b) ↑ (Gao <i>et al</i> , 2009) • (Xue <i>et al</i> , 2008)			
Trimethylamine N-oxide	00925	Microbial co-metabolite		↓ (Shariff <i>et al</i> , 2011; Chen <i>et al</i> , 2011b)		
Creatine	00064	Other		↓ (Chen <i>et al</i> , 2011b) ↑ (Shariff <i>et al</i> , 2010, 2011)		
Hypoxanthine	00157	Purine nucleoside		↓ (Wu <i>et al</i> , 2009) ↑ (Chen <i>et al</i> , 2009, 2011b)		
2-Oxoglutarate	00208	TCA cycle	↑ (Gao <i>et al</i> , 2009, Chen <i>et al</i> , 2011b)			
Succinate	00254	TCA cycle		↓ (Wu <i>et al</i> , 2009; Chen <i>et al</i> , 2011b)		

Abbreviation: AA = amino acid; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HMDB = The Human Metabolome Database; TCA = tricarboxylic acid. ↓ indicates decrease in HCC; ↑ indicates increase in HCC; † indicates control group of the study (Huang *et al*, 2013; Wei *et al*, 2012) comprised chronic HCV or HBV carriers, respectively.

included 13 serum components had an overall accuracy of 75% in discriminating HCC from healthy controls (Xue *et al*, 2008). Only one urinary study evaluated the performance of an established PCA model for discriminating between HCC patients and healthy controls. Their model included 18 urinary compounds plus serum AFP and performed much better than AFP, with an AUC of 0.928 (Wu *et al*, 2009). Taken together, these models seem to suggest that a robust diagnostic of HCC could be produced with a reduced panel of biomarkers rather than using the whole spectroscopic dataset. However, given that the panels of biomarker thus far reported in the literature have not been assessed in independent validation cohorts, there is now a pressing requirement for driving a full validation study for a selected biomarker panel.

HCC markers proposed by MS-based proteomics

State of the science. The PubMed search conducted using the search term stated in the Methods section resulted in the selection of 171 references. These were initially screened by methodology and all publications not utilising MS as a primary discovery

approach were filtered out. The remaining references were read for adherence to the specified inclusion criteria leading to the exclusion of a further 31, leaving 29 to be used in this paper. Early studies applying MS techniques to clinical proteomics biomarker research exerted a greater focus on the utilisation of SELDI/MALDI ionisation platforms, occasionally coupled with weak/strong ion-exchange chromatography techniques for the identification of protein marker candidates. The MS analysis was typically applied in concert with two-dimensional electrophoresis methods where proteins separated according to their isoelectric points and molecular weights were observed on a global scale. Notable points of differentiation in spot patterns correlating with disease groupings would be excised for identification following in-gel digestion. Alternative approaches to marker discovery, which have since become more popular include untargeted analyses using tandem MS fragmentation methods to break up chromatographically separated proteins expressed in clinical samples followed by database-driven identification (Nesvizhskii, 2007). Both these approaches are applicable to pre-fractionated or un-fractionated

samples as well as those which have undergone pre-enrichment steps for particular post-translational modifications (PTMs) of interest; a major form of this being glycosylation changes. This general shift from the coupling of gel-based classical proteomic approaches with MS to standalone chromatography-MS platforms has enabled researchers a greater detail in the analysis of the human proteome as well as increased flexibility and unmatched depth in finding biomarker targets.

Protein families. Proteomic exploration using MS is widely focussed on serum and plasma, which form the key body fluids with the greatest dynamic range of protein expression. This review of protein markers for HCC determined by MS in various populations identifies candidates from a wide range of protein families. Acute-phase and transport proteins, enzymes as well as proteins involved in various complementary and lipid metabolic pathways form some of the most commonly reported classes of biomarker candidates. Alongside these, a smaller number of proteins involved in numerous functions ranging from apoptosis, ion transport, host immunity, iron homeostasis, protection from toxins and oxidative stress, cell adhesion, differentiation, regeneration, and death are reflected in the list of reported markers (Table 8). As the most frequently proposed protein subtype for biomarker candidates, the suggestion of acute-phase proteins as biomarker candidates is often eyed with scepticism as they are seen to lack specificity for particular disease processes. These proteins, however, constitute a well validated subset of proposed markers suggested from experiments run on numerous MS platforms in the context of HCC and CLDs. A1AT and alpha-1-antichymotrypsin (AACT) are major acute-phase proteins, which serve as protease inhibitors protecting tissues from the enzymatic action of inflammatory cells. Five independent publications identified these proteins as elevated in HCC patients; with a highest reported fold change of 5.3. Another large subset of proteins often reported following MS interrogation of HCC samples are apolipoproteins. These are proteins that bind lipids and cholesterol in the blood and lymphatic systems. Several isoforms, namely Apo A1, Apo J, Apo L1, and Apo B-100 have been consistently reported as downregulated in HCC. In particular, Apo J in its association with HCC has been implicated as a possible indicator of the metastatic potential of primary tumours (Lau *et al*, 2006). In overall performance reports, some of the most consistently highlighted proteins include those with functional properties such as ion transport and scavenging, in particular – iron homeostasis. Haptoglobin and haemopexin are key players in the maintenance of haemoglobin and free haem in the blood. Haptoglobin binds free haemoglobin with high affinity and thus protects cells from its oxidative effects. Haemopexin on the other hand binds free haem released in the turnover of erythrocytes and preserves the body's iron stores. Like most of the proteins with unique expression trends concordant with liver disease, the specific mechanisms linking these proteins to CLD are not understood. However, amalgamated reports demonstrate that haptoglobins are largely increased in blood from HCC patients. Haemopexin in its whole and fucosylated forms follow the same trend with a suggestion in one report of a decrease in LC (Fye *et al*, 2013).

Challenging discrepancies. This review identifies 31 individual proteins as showing differential signatures associated with a stage of liver disease. Each of these have undergone at least one level of validation whether in the context of the same publication or in an independent report. Overall, the direction of the alterations in protein expression are uniform, there however are some specific proteins, namely alpha-1-acid glycoprotein, afamin, complement component 3, and haptoglobin-related protein that demonstrate discrepancies in behaviour in selected case-control groupings. Alpha-1-acid glycoprotein, for example, is reported to be downregulated in HCC's in comparison to cirrhotics by one group (Lee

et al, 2011) and upregulated in HCC's vs LC's by another (Kang *et al*, 2010). Complement component 3 shows a similar discrepancy in two studies (Steel *et al*, 2003; Ahn *et al*, 2012b). In each of these cases, key differences related to HCC assessment, sample pretreatment and MS platform used are likely contributors to the lack of consistency observed. Numerous publications included in this review and directly implicated in these discrepant examples have little to no clinical information on how LC or HCC cases were diagnosed (Ishihara *et al*, 2011; Ahn *et al*, 2012b), not to mention an almost uniform lack of staging data. For proteomic analyses in particular, different approaches exist to sample pretreatment, with options to deplete key abundant proteins, enrich for, or exclude (Lee *et al*, 2011) particular PTMs. With albumin constituting ~60% of the total protein content of blood (Shen *et al*, 2004) and forming the backbone of many protein-protein interactions and complexes, its depletion could contribute to the loss of important endogenous signatures. Varying depletion protocol efficiencies may also impact directly on the accuracy of downstream quantitation. Additional separation by isoelectric or electrophoretic analysis according to molecular weight or isoelectric point whether 'in' or 'off-gel' can be applied to neat or pre-treated samples meaning that the final matrix injected into the MS instrument may already be severely biased towards identification of selected protein subtypes or sizes. This phenomenon along with varying MS platforms and ionisation methods will all contribute to the differences observed in shortlisted marker profiles at final analyses. Thus, the quantitative data assembled, though important cannot always be taken as conclusively reflective of endogenous expression. This can only be adequately assessed by targeted measurement of whole proteins using highly specific antibody-based methods or absolute quantitation by S/MRM MS analysis of unique peptide sequences in well-characterised sample cohorts.

Glycosylation and HCC. An area of particular focus in terms of identifying unique exploitable changes for differential CLD diagnosis are those which occur in the glycosylation of many proteins during liver disease progression (Blomme *et al*, 2009). Glycosylation is essential to the tertiary and quaternary structures of many proteins bearing direct impact on their solubility and transport. The carbohydrate moieties bound to these modified proteins can be directly impacted by changes in host immunity and carcinogenesis. The surface of hepatocytes contain various receptors that bind proteins via their carbohydrate groups; when changes to the liver surface occur as a result of fibrosis, cirrhosis, or HCC, alterations in receptor distribution can lead to the accumulation of certain glycoproteins in the blood, which can be picked up by methods such as MS. As asparagine-linked (N-linked) glycosylation is the predominant form found in human sera, much research has been focussed on this particular subclass of glycoproteins. Investigations looking at the glycosylation patterns of key serum proteins associated with HCC and LC reports evidence of hyperfucosylation for 19 glycoproteins (Comunale *et al*, 2006) in the context of liver disease. Mass spectrometric assays conducted on lectin-enriched samples are seen to represent a sizable fraction of the protein markers identified in this review. Fucosylated haemopexin stands out as one of the highest performing candidate markers for HCC diagnosis with a reported AUC of 0.95 (Comunale, 2009). Numerous additional publications using lectin enrichment steps prior to MS analysis have identified various glycosylated proteins such as alpha-1-acid glycoprotein 1 (A1AG1), AACT, Apo L1, Apo J (Ahn *et al*, 2012a, b), and several complement proteins as differentially expressed in HCC vs other disease stages. The multiply reported decline in the blood levels of various isoforms of the apolipoproteins involved in lipid and cholesterol metabolism have also been demonstrated to hold significant association with HCC.

Table 8. Summary of proteomic studies that were reviewed

Protein (key role)	UniProt ID	Biofluid	Relation to HCC (↑, ↓)	HCC LB rate	Cohort sizes	Aetiology	AUROC	Fold change	Platform	Reference
AGP1 (AP: Transport)	P02763	Plasma	↑ HCC:CON	No information	*10 HCC; 30 controls (healthy/LC/HBV)	HBV	0.73	1.6*	Lectin MRM-UPLC-ESI-MS	Ahn et al, 2012a, b*
		Plasma	↓ HCC:LC	No information	Disc: 10 HCC/2 HCON Val: 18 HCC, 10 HCON	No information	0.65	—	nUPLC-ESI-QTOF-MS and QQQ	Lee et al, 2011
A1AT (AP: Protease inhibitor)	P01009	Serum	↑ HCC:LC	100% ALL	Disc: 9 HCC/9 LC Val: 52 HCC/40 LC	HBV	—	1.8 [†]	ICAT-LC-ESI-MS/MS	Kang et al, 2010
		Plasma	↑ HCC:CON	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	0.84	—	QTOF-LC-MS, ELISA	Fye et al, 2013
A2M (Protease inhibitor)	P01023	Plasma	↑ HCC:CON	No information	*10 HCC; 30 controls (healthy/LC/HBV)	HBV	0.92	2.4**	Lectin MRM-UPLC-ESI-MS	Ahn et al, 2012a, b*
		Serum	↑ HCC:CON	No information	Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON	HBV	—	—	MALDI-TOF-MS/MS, 2DE	Feng et al, 2005
AACT (AP: Protease inhibitor)	P01011	Plasma	↑ HCC:CON	No information	*10 HCC; 30 controls (healthy/LC/HBV)	HBV	0.93	3.7**	Lectin MRM-UPLC-ESI-MS	Ahn et al, 2012a, b*
		Plasma	↑ HCC:CON	No information	6 HCC, 3 HCON	No information	—	5.3*	2D LC-MALDI-TOF/TOF	Ishihara et al, 2011
AFM (Vitamin transport)	P43652	Plasma	↑ HCC:CON	No information	6 HCC, 3 HCON	No information	—	33.1 [†]	2D LC-MALDI-TOF/TOF	Ishihara et al, 2011
		Plasma	↓ HCC:CON	No information	28 HCC, 10 HCON	No information	0.72	—	nUPLC-ESI-QTOF-MS and QQQ	Lee et al, 2011
Apolipoproteins										
Apo A1 (Cholesterol metabolism)	P02647	Plasma	↓ HCC:CON	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	0.83	—	QTOF-nUPLC-ESI-MS	Fye et al, 2013
		Serum	↓ HCC:CON	100% of HCCs	20 HCC, 20 HCON	No information	—	-3.59*	2DE-coupled MALDI-TOF-MS	Sun et al, 2010b
		Serum	↓ HCC:CON	100% of HCCs	8 HCC, 21 HBV, 7 HCON	HBV	—	-3.10 [†]	2DE-coupled MALDI-TOF-MS	Steel et al, 2003
Apo B-100 (Cholesterol metabolism)	P04114	Plasma	↓ HCC:CON	No information	6 HCC, 3 HCON	No information	—	-3.7*	2D LC-MALDI-TOF/TOF	Ishihara et al, 2011
Apo L1 (Cholesterol metabolism)	O14791	Plasma	↓ HCC:CON	No information	*10 HCC; 30 controls (healthy/LC/HBV)	HBV	0.68	0.5 ^{ns}	Lectin MRM-UPLC-ESI-MS	Ahn et al, 2012a, b*
B2M (Immunity)	P61769	Plasma	↑ HCC:CON	No information	6 HCC, 16 LC/HBV/HCV, 8 HCON	HCV/HBV	—	—	SELDI-TOF-MS	Nakatsura, 2010
		Serum	↑ HCC:pre-HCC	Some Histo. % not stated	38 Pre-HCC; 35 samples upon clinical diagnosis of HCC; 18 samples post treatment (longitudinal collection)	HCV	—	1.82**	SELDI-TOF-MS	Ward et al, 2006
C4B- α (Complement pathway)	P04003	Plasma	↑ HCC:CON	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	—	1.25 ^{ns}	QTOF-nUPLC-ESI-MS	Fye et al, 2013
CC3 (Complement pathway)	P01024	Plasma	↑ HCC:CON	No information	*10 HCC; 30 HCON/LC/HBV	HBV	0.66	1.3 ^{ns}	Lectin MRM-UPLC-ESI-MS	Ahn et al, 2012a, b*
		Plasma	↑ HCC:LC	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	0.67	2.0 ^{ns}	Lectin MRM-ESI-UPLC-MS	Ahn et al, 2012b
CC3- α	P01024	Serum	↓ HCC:CON	100% of HCCs	8 HCC, 21 HBV, 7 HCON	HBV	—	-1.87**	QTOF-nUPLC-ESI-MS, ELISA	Fye et al, 2013
		Serum	↑ HCC:CLD/CON	No LBs done	45 HCC, 42 CLD, 21 HCON	HCV	0.70	—	2DE-coupled MALDI-TOF-MS	Steel et al, 2003
			↑ HCC:CLD/CON	No information	28 HCC, 10 HCON	HCV	—	n/r but P of Δ 0.00001	SELDI-TOF-MS, WB	Kanmura et al, 2010 Lee et al, 2006

Table 8. (Continued)

Protein (key role)	UniProt ID	Biofluid	Relation to HCC (↑, ↓)	HCC LB rate	Cohort sizes	Aetiology	AUROC	Fold change	Platform	Reference
CERU (Cu/ion transport)	P00450	Plasma	↑ HCC:CON	No information	10 HCC; 30 HCON/LC/HBV)	HBV	0.77	1.5**	Lectin MRM-UPLC-ESI-MS	Ahn <i>et al</i> , 2012b
		Plasma	↑ HCC:CON	No information	6 HCC, 3 HCON	No information	—	6.8†	2D LC-MALDI-TOF/TOF	Ishihara <i>et al</i> , 2011
		Serum	HCC only	100% of HCCs	5 HCC, 5 HCON	HCV/HBV	—	—	nanoHPLC-ESI-MS/MS	Yang <i>et al</i> , 2007a
		Serum	↑ HCC:CON	No information	Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON	HBV	—	—	2DE and MALDI-TOF-MS/MS	Feng <i>et al</i> , 2005
CLU (apoptosis/complement pathway)	P10909	Plasma/serum	↓ HCC:CON	No information	No information	No information	—	—	SID-MRM-MS	Zhao <i>et al</i> , 2010
		Plasma	↓ HCC:CON	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	—	0.59*	QTOF-nUPLC-ESI-MS	Fye <i>et al</i> , 2013
		Plasma	↓ HCC:CON	No information	10 HCC; 30 HCON/LC/HBV	HBV	0.70	0.8 ^{ns}	Lectin MRM-UPLC-ESI-MS	Ahn <i>et al</i> , 2012a, b
		Serum	↑ HCC:CON	No information	Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON	HBV	—	—	2DE and MALDI-TOF-MS/MS	Feng <i>et al</i> , 2005
ERBB3 (Signalling pathway)	P21860	Serum	↑ HCC:LC/CON	Disc and Val 1-100% Val 2; Unclear	Disc: 10 total, HCC and non-HCC Val 1: 113 HCC, 47 LC, 64 HBV/HCV Val 2: 57 HCC, 35 HBV/HCV	HBV/HCV	0.93/0.71	—	MALDI-TOF-MS, WB, ELISA	Hsieh <i>et al</i> , 2011
GFAP (cell differentiation/regeneration) hCE1 (response to toxins)	P14136	Serum	↑ HCC:CON	100% HCCs	Disc: 20 HCC, 20 HCON Val: 5 HCC, 5 HCON	No information	—	—	2DE-coupled MALDI-TOF, WB	Wu <i>et al</i> , 2012
	P23141	Plasma	↑ HCC:CON	No information	24 HCC, 14 LC, 7 CH, 8 CCA, 15 stomach cancer, 16 pancreatic cancer	No information	0.80	—	2DE MALDI-TOF/TOF, nano-LC MS/MS, WB	Na <i>et al</i> , 2009
HP (AP: Immunity and Fe homeostasis)	P00738	Serum	↑ HCC:CON	100% of HCCs	5 HCC, 5 HCON	HCV/HBV	—	—	2DE LC-ESI-MS/MS	Yang <i>et al</i> , 2007a
		Serum	↑ HCC:CLD	100% of HCCs	56 HCC, 40 CLD	No information	0.73	2.57**	ELISA	Ang <i>et al</i> , 2006
		Serum	↑ HCC:CON	No information	Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON	HBV	—	—	2DE and MALDI-TOF-MS/MS	Feng <i>et al</i> , 2005
		Serum	↑ HCC:CON	100% of HCCs	20 HCC, 20 HCON	No information	—	5.10**	2DE-coupled MALDI-TOF-MS	Sun <i>et al</i> , 2010b
		Plasma	↑ CON:LC	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	—	1.35*	QTOF-nUPLC-ESI-MS	Fye <i>et al</i> , 2013
HPR (metabolic process)	P00739	Serum	↑ HCC:CON	100% of HCCs	5 HCC, 5 HCON	HCV/HBV	—	—	2DE LC-ESI-MS/MS	Yang <i>et al</i> , 2007a
		Plasma	↓ HCC:CON	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	—	0.65*	QTOF-nUPLC-ESI-MS	Fye <i>et al</i> , 2013
HPX (Fe homeostasis)	P02790	Plasma	↑ HCC:CON	No information	10 HCC; 30 HCON/LC/HBV	HBV	0.61	1.2 ^{ns}	Lectin MRM-UPLC-ESI-MS	Ahn <i>et al</i> , 2012b
		Plasma	↑ CON:LC	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	0.81	—	QTOF-nUPLC-ESI-MS	Fye <i>et al</i> , 2013
Fu-HPX		Plasma	↑ HCC:CON	Some Histo. % not stated	72 HCC, 32 LC, 33 HBV, 133 HCV, 62 other liver diseases, 20 CON	HCV/HBV	0.95	1.4**	Lectin LC-MS/MS	Comunale, 2009
HSP90 (stress response) OPN (biomineralisation/cell adhesion)	P08238	Serum	↑ HCC:CON	100% of HCCs	20 HCC, 20 HCON	No information	—	7.04**	MALDI-TOF-MS, ELISA	Sun <i>et al</i> , 2010b
	P10451	Plasma	↑ HCC:CLD/CON	Val: None	Disc: 17 HCC, 18 LC Val: 131 HCC, 76 LC, 52 CHCV/HBV, 53 HCON	HCV/HBV	0.76	—	LC-ESI-MS/MS with 2D nHPLC-coupled LTQ	Shang <i>et al</i> , 2012
		Plasma	↑ HCC:CON/LC	Some Histo. % not stated	30 HCC, 30 LC, 20 HCON	HCV	0.92	4.33†	OrbiTrap ELISA	El-Din Bessa <i>et al</i> , 2010

Table 8. (Continued)

Protein (key role)	UniProt ID	Biofluid	Relation to HCC (↑, ↓)	HCC LB rate	Cohort sizes	Aetiology	AUROC	Fold change	Platform	Reference
PON-1 (antioxidant/hydrolase)	P27169	Serum	↑ HCC:CON	100% of HCCs	5 HCC, 5 HCON	HCV/HBV	—	—	2DE LC-ESI-MS/MS	Yang <i>et al</i> , 2007a
		Plasma	↓ HCC:CON	Disc 24.2% Val 4.8%	Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON	HBV/ aflatoxin	—	0.63**	QTOF-nUPLC-ESI-MS	Fye <i>et al</i> , 2013
Prx-II (antioxidant/oxidoreductase/peroxidase)	P32119	Plasma	↑ LC:CON	100% of cases	Disc: 27 HBV, 7 HCON Val: 68 HBV, 42 HCON	HBV	1.00	—	MALDI-TOF-MS	Lu <i>et al</i> , 2010
		Tissue	↑ HCC:CON	100% of HCCs	6 HCC, 6 non-malignant adjacent tissue	HBV	—	2.1 [†]	2DE-coupled MALDI-TOF-MS	Matos <i>et al</i> , 2009
SAA (AP and innate response/cell adhesion)	P0DJ18	Serum	↑ HCC:CON	No information	67 HCC, 53 CHBV, 44 HCON	HBV	—	4.5 [†]	2DE MALDI-TOF-MS, SELDI-TOF-MS	He <i>et al</i> , 2008
		Serum	HCC only	100% of HCCs	5 HCC, 5 HCON	HCV/HBV	—	—	2DE LC-ESI-MS/MS	Yang <i>et al</i> , 2007a
SGP-2 (cell death)	Q6LDQ3	Serum	↑ HCC:CON	100% HCCs	Disc: 20 HCC, 20 HCON Val: 5 HCC, 5 HCON	No information	—	—	2DE MALDI-TOF-MS, WB	Wu <i>et al</i> , 2012
TGM2 (apoptosis/transferase)	P21980	Tissue/serum	↑ HCC:CON	ALL: 100% of HCCs	Tissue disc: 61 HCC, 61 adjacent non-tumour tissue Val: 109 HCC, 42 HCON	HBV/HCV	—	—	LTO-FT-MS/MS, ELISA	Sun <i>et al</i> , 2008
TTR (Transport)	P02766	Serum	↓ HCC:CON	No information	Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON	HBV	—	—	2DE and MALDI-TOF-MS/MS	Feng <i>et al</i> , 2005
		Serum	↓ HCC:CON	100% of HCCs	5 HCC, 5 HCON	HCV/HBV	—	—	2DE LC-ESI-MS/MS	Yang <i>et al</i> , 2007a
VIM (host-virus interaction)	P08670	Tissue/serum	↑HCC:LC/CON	Disc: 100% of HCCs Val: No information	Disc (tissue): 40 HCC, 36 CON Val: 88 HCC, 64 CON	HBV	0.69	3.27 [†]	2DE MALDI-TOF/TOF, ELISA	Sun <i>et al</i> , 2010a
VIT (cell adhesion)	P04004	Serum	↑ HCC:LC	91% of HCCs	44 HCC, 38 LC	No information	0.85	—	SELDI-TOF-MS	Paradis <i>et al</i> , 2005
		Serum	↓ HCC:CON	No information	10 HCC, 10 HCON	No information	—	—	SID-MRM-MS	Zhao <i>et al</i> , 2010
		Plasma	↑ HCC:CON	No information	10 HCC; 30 HCON/LC/HBV	HBV	0.54	1.1 ^{ns}	Lectin MRM-UPLC-ESI-MS	Ahn <i>et al</i> , 2012b
		Plasma	↓ HCC:CON	No information	28 HCC, 10 HCON	No information	0.98	—	nUPLC-ESI-QTOF-MS and QQQ	Lee <i>et al</i> , 2011

Abbreviations: 2D = two dimensional; 2DE = two-dimensional electrophoresis; ASC = asymptomatic carrier; AUROC = area under receiver operating characteristics; CCa = cholangiocarcinoma; CHBV/CHCV = chronic HBV or HCV; CLD = chronic liver disease; ELISA = enzyme-linked immunosorbent assay; ESI = electrospray ionisation; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCON = healthy control; HCV = hepatitis C virus; Histo = histology; ICAT = isotope-coded affinity tag; LB = liver biopsy; LC = liquid chromatography; MALDI = matrix-assisted laser desorption/ionization; MRM = multiple reaction monitoring; MS = mass spectrometry; n/r = not recorded; nanoHPLC = nano high-performance liquid chromatography; nUPLC = nano ultra-performance liquid chromatography; QQQ = triple quadrupole mass spectrometer; qTOF = quadrupole time of flight; WB = western blot; SELDI = surface-enhanced laser desorption/ionization; TOF = time-of-flight. * $P < 0.05$; ** $P < 0.01$; ns, non-significant; †, no P -value reported.

Critical assessment and performance comparisons. In the presentation of candidates as potential biomarkers for HCC or any other condition; there has to be a widely applicable tool of measurement offering universal assessment of the potential usefulness and validity of a marker. Area under the curve reports with its achievable sensitivity and specificity at a chosen cut-off and fold change statistics form the most widely employed tools, and have become the benchmarks used for comparative assessment of candidates. Few studies report both AUC and fold change statistics as is seen in the comprehensive tables presented (Tables 2 and 8). As AFP is the only established non-invasive tool used for HCC diagnosis – all biomarker studies are in effect in competition with its performance. One major gap, which exists in making comparative assessments with AFP within and across studies is that oftentimes the test forms an intrinsic part of the initial diagnostic profile used to classify subjects into the various clinical groups under evaluation. Without direct comparison of AFP and the gold standard in HCC diagnosis of liver biopsy within the *same* subject populations, no true evaluation of AFP performance can be accepted as an accurate reference point. In the absence of this, most publications are either mute on this point or address it by basing their performance evaluations on reported estimates for AFP

performance often ranging between 0.6 and 0.7 with some dipping lower (Giannini *et al*, 2012).

DISCUSSION AND CONCLUSION

This review serves as a focus for summarizing and highlighting metabonomic and proteomic literature on biomarkers for HCC in the urine and blood. A multitude of biomarker candidates have been proposed by comparative ¹H NMR or MS analysis of urine and/or blood from HCC patients and various CLD groups. A review of these studies has shown that noteworthy changes occur at both the metabolite and protein levels, which correlate with disease aetiology and/or progression. Of significant note however are the multitudes of candidates, which do not appear to be reproducible but nevertheless weigh heavily on literature reports. These are vast in number and were filtered from this review, as they detracted from its stated aims. In order to move forward and accelerate the conversion of biomarker candidates into routine and robust tests to be used in clinics and the field, particularly in the developing world, this area of research must be held to a minimum standard of uniformity (Table 9) and from this facilitate a momentum shift

Table 9. Recommendations for future metabolomic and proteomic studies on HCC

Key point	Recommendation
Use of published guidelines to inform case definitions	CLD diagnosis should be made using agreed international guidelines (e.g., EASL and AASLD). New guidelines must be developed/adapted for areas of HCC endemicity in the developing world
Measure of total protein expression	Use commercial assays (e.g., QuantiPro BCA) to quantify and normalise total protein expression in sampled blood
Prandial state	8–12 h Pre-prandial
Physical exercise	Should be avoided immediately prior to sample collection
Overall liver function	Assessment of Child-Pugh score: A: Hepatic compensated B: Slightly decompensated liver state C: Hepatic decompensated
Tumour size and nodularity	Tumour staging, for example, TMN classification
Comorbidities	Clinical assessment of cirrhosis in the background of HCC Clinical assessment of renal impairment, for example, kidney function tests such as glomerular filtration rate (important for urinary analyses)
Tumour size and nodularity	Tumour staging, for example, TMN classification
Validation of the diagnostic model	Inclusion of external validation cohorts, for example, early HCCs, different HCC aetiologies, and tumour controls
Performance assessment of the diagnostic model	AUROC statistic, enables direct comparison to other models and AFP
Abbreviations: AASLD = American Association for the Study of Liver Diseases; AFP = alpha-fetoprotein; AUROC = area under receiver operating characteristics; BCA = bicinchoninic acid; CLD = chronic liver disease; EASL = European Association for the Study of the Liver; HCC = hepatocellular carcinoma; TMN = tumour, nodes, and metastasis.	

from discovery to validation-based experiments. A noteworthy example is a recently conducted imaging MS study, which validated an altered phospholipid composition in HCC tumour tissues by transcriptomic analyses, thereby identifying LPCAT1 as a potential target molecule to inhibit HCC progression. A key limitation identified from the amalgamation of these reports, which is of particular significance in investigations targeting metabolites is the limited availability of descriptive statistics such as ROC analyses and fold change ratios offering quantitative measures of assessing the performance of a putative marker. Also missing in many studies are any efforts at validating the proposed biomarkers in distinct population sets. In both the proteomic and metabolomic papers reviewed, < 15% of publications included any attempts at independent validation of results. Without a consistent ability to reproduce primary discovery results in diverse populations, biomarkers will not accelerate on the pipeline towards serious consideration.

It is recognised that routine liver biopsy assessment of suspected HCCs is not readily available in many populations where the condition is endemic. The relevance of biopsy sample retrieval and definitive tumour staging however, cannot be overstated. For any new HCC diagnostic test to have a direct impact on reducing mortality from end-stage liver disease, it must be able to discern those at highest risk of progression to HCC from a background of LC or fibrosis as well as reflect early changes in the liver related to tumourigenesis. Most of the markers included in this review have been proposed from heterogeneous case groups where considerations such as background health of liver, tumour stage, and severity of cirrhosis or fibrosis have not been assessed or are not reported. Thus, when these candidates are proposed for validation studies, accurate case profiles must be presented that clearly stratify HCC stages in order to home in on how candidates perform in the diagnostic groups most difficult to distinguish. Best practice would warrant the clear and comprehensive distinction of these at the discovery stage but this is yet to be reflected in current practice. Some metabolites are correlated with the degree of cirrhosis or the hepatic compensation status of patients. For example, the metabolic profile of patients with small HCC tumours on a background of severe cirrhosis differs significantly from late HCC with minor background cirrhosis (Nahon *et al*, 2012b). Group heterogeneity can thus bias results and impact directly on the range of proteins, metabolites, or pathways detected as significantly

different. Such comprehensive descriptions and assessments are largely absent from current HCC biomarker literature and must be incorporated and prioritised in order to identify biomarker signatures of the highest impact.

Although the majority of studies presented provide detailed demographic data for participants, there was an observed lack of consistency in which clinical indices were reported in published works. Reports on liver biopsy rates and AFP levels are arguably of primary relevance to any HCC biomarker studies yet figures for these were present only in a fraction of papers. For AFP in particular, the cut-off taken as indicative of HCC, where reported, was still highly variable, ranging from 20 to 500 ng ml⁻¹ depending on the specific study population or chosen guidelines. Alongside this, details on overall liver health, liver compensation status, clinical chemistry tests (e.g., liver enzymes and bilirubin), and the treatment status of participants were at best inconsistently reported. The absence or lack of consideration of these key clinical parameters will undoubtedly have significant implications on participant selection and classification as well as the interpretation of disease-specific signatures. Thus, a key recommendation to be made following this review is the need for some degree of uniformity in the rationale and level of detail forming the basis of case and control selection. Providing detailed case definitions would reduce or at least allow for the contextualisation of marked variations, which exist in the selection of cohorts. This could perhaps contribute to a wider overlap in identified proteins and metabolites associated with CLDs across different investigative platforms and thus offer greater consensus on which targets to validate.

In order to move some of the many suggested HCC biomarker targets forward and accelerate their conversion into routine and robust tests usable in clinics and the field, particularly in the developing world, the momentum of research must now shift from discovery to validation-based experiments – focused both on expression level and mechanistic changes between clinically distinct groups. The populations involved in these studies must be well characterised to dissect biomarkers that are specific for (early) HCC and if these are still valid, in the presence of cirrhosis or other comorbidities. Below, we summarise key points that can significantly bias the results of a biomarker study on HCC. At the same time, we give recommendations, which with careful consideration could raise the likelihood of successful conversion of proposed biomarkers in the field of HCC research.

Although the consideration of these points and recommendations will not lead to uniform impact for all researchers in this field due to the diversity of challenges faced, it is however important that they are recognised as highly relevant and begin to be discussed on a larger scale.

REFERENCES

- Ahn YH, Ji ES, Shin PM, Kim KH, Kim YS, Ko JH, Yoo JS (2012a) A multiplex lectin-channel monitoring method for human serum glycoproteins by quantitative mass spectrometry. *Analyst* **137**: 691–703.
- Ahn YH, Shin PM, Oh NR, Park GW, Kim H, Yoo JS (2012b) A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. *J Proteomics* **75**: 5507–5515.
- Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, Hui AY, Johnson PJ, Sung JJ (2006) Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. *J Proteome Res* **5**: 2691–2700.
- Baniyasi H, Gowda GA, Gu H, Zeng A, Zhuang S, Skill N, Maluccio M, Raftery D (2013) Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. *Electrophoresis* **34**: 2910–2917.
- Baptissart M, Vega A, Maqdasy S, Caira F, Baron S, Lobaccaro JM, Volle DH (2013) Bile acids: from digestion to cancers. *Biochimie* **95**: 504–517.
- Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V (2003) Carnitine and hemodialysis. *Am J Kidney Dis* **41**: S116–S122.
- Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS (2012) Hepatocellular carcinoma serum markers. *Semin Oncol* **39**: 410–433.
- Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM (2010) Prognostic and diagnostic value of des-gamma-carboxy prothrombin in liver cancer. *Drugs News Perspect* **23**: 498–508.
- Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, Di Carlo I (2014) Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. *Biomed Res Int* **2014**: 203693.
- Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I (2011) Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. *Minerva Med* **102**: 363–371.
- Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR (2013) Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. *Hepatology* **58**: 229–238.
- Biondi A, Malaguarnera G, Vacante M, Berretta M, D'Agata V, Malaguarnera M, Basile F, Drago F, Bertino G (2012) Elevated serum levels of chromogranin A in hepatocellular carcinoma. *BMC Surg* **12 Suppl 1**: S7.
- Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H (2009) Alteration of protein glycosylation in liver diseases. *J Hepatol* **50**: 592–603.
- Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorn Dahl TC, Krishnamurthy R, Saleem F, Liu P, Dame ZT, Poelzer J, Huynh J, Yallou FS, Psychogios N, Dong E, Bogumil R, Roehring C, Wishart DS (2013) The human urine metabolome. *PLoS One* **8**: e73076.
- Boyle P, Levin B (2008) World cancer report 2008.
- Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update (2011) *Hepatology* **53**: 1020–1022.
- Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA (2006) Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. *J Nutr Biochem* **17**: 73–88.
- Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, McClave SA (2008) Obesity, inflammation, and the potential application of pharmaconutrition. *Nutr Clin Pract* **23**: 16–34.
- Chen F, Xue J, Zhou L, Wu S, Chen Z (2011a) Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabolomic method. *Anal Bioanal Chem* **401**: 1899–1904.
- Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, Zhang F, Xu G (2009) Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. *Anal Chim Acta* **650**: 3–9.
- Chen S, Kong H, Lu X, Li Y, Yin P, Zeng Z, Xu G (2013a) Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry. *Anal Chem* **85**: 8326–8333.
- Chen S, Yin P, Zhao X, Xing W, Hu C, Zhou L, Xu G (2013b) Serum lipid profiling of patients with chronic hepatitis B, cirrhosis, and hepatocellular carcinoma by ultra fast LC/IT-TOF MS. *Electrophoresis* **34**: 2848–2856.
- Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W (2011b) Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. *Mol Cell Proteomics* **10**: M110 004945.
- Chen Y, Xu Z, Kong H, Chen N, Chen J, Zhou L, Wang F, Dong Y, Zheng S, Chen Z, Xu G, Li L (2012) Differences between the metabolic profiles of decompensated and compensated cirrhosis patients with hepatitis B virus infections under high-performance liquid chromatography-mass spectrometry. *Metabolomics* **8**(5): 845–853.
- Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhagen B, Long RE, Junaidi O, Bisceglie AM, Block TM, Mehta AS (2009) Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. *J Proteome Res* **8**(2): 595–602.
- Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, Evans AA, Hann HW, Block TM, Mehta AS (2006) Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. *J Proteome Res* **5**: 308–315.
- Dodson WL, Sachan DS, Krauss S, Hanna W (1989) Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. *J Am Coll Nutr* **8**: 133–142.
- El-Din Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH (2010) Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. *Arch Med Res* **41**: 541–547.
- El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* **132**: 2557–2576.
- European Association for the Study of the Liver/European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* **56**: 908–943.
- Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY (2005) Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. *Proteomics* **5**: 4581–4588.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* **127**: 2893–2917.
- Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q (2010) Role of carnitine in disease. *Nutr Metab* **7**: 30.
- Fye HK, Wright-Drakesmith C, Kramer HB, Camey S, Nogueira da Costa A, Jeng A, Bah A, Kirk GD, Sharif MI, Ladep NG, Okeke E, Hainaut P, Taylor-Robinson SD, Kessler BM, Mendy ME (2013) Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west african populations. *PLoS One* **8**: e68381.
- Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW (2011) Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* **60**: 463–472.
- Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, Evans C, Weiss RH (2012) Urinary acylcarnitines are altered in human kidney cancer. *Int J Cancer* **130**: 2791–2800.
- Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D (2009) Application of 1H NMR-based metabolomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. *Cancer Sci* **100**: 782–785.
- Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegna L, Zoli M, Borzio F, Caturelli E, Chiamonte M, Trevisani F. Italian Liver Cancer (ITA.LI.CA) group (2012) Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. *Hepatology* **56**: 1371–1379.

- He QY, Zhu R, Lei T, Ng MY, Luk JM, Sham P, Lau GK, Chiu JF (2008) Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. *J Cell Biochem* **103**: 740–752.
- Heuberger W, Berardi S, Jacky E, Pey P, Krähenbühl S (1998) Increased urinary excretion of carnitine in patients treated with cisplatin. *Eur J Clin Pharmacol* **54**: 503–508.
- Hoi PM, Hiley CR (2006) Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. *Br J Pharmacol* **147**: 560–568.
- Hoppel C (2003) The role of carnitine in normal and altered fatty acid metabolism. *Am J Kidney Dis* **41**: S4–S12.
- Hsieh SY, He JR, Yu MC, Lee WC, Chen TC, Lo SJ, Bera R, Sung CM, Chiu CT (2011) Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. *J Proteome Res* **10**: 4715–4724.
- Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, Xu G (2013) Metabolic characterization of hepatocellular carcinoma using non-targeted tissue metabolomics. *Cancer Res* **73**: 4992–5002.
- Ishihara T, Fukuda I, Morita A, Takinami Y, Okamoto H, Nishimura S, Numata Y (2011) Development of quantitative plasma N-glycoproteomics using label-free 2-D LC-MALDI MS and its applicability for biomarker discovery in hepatocellular carcinoma. *J Proteomics* **74**: 2159–2168.
- Kang X, Sun L, Guo K, Shu H, Yao J, Qin X, Liu Y (2010) Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS. *J Cancer Res Clin Oncol* **136**: 1151–1159.
- Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K, Stuver SO, Tsubouchi H (2010) The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. *J Gastroenterol* **45**: 459–467.
- Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL (2013) Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med* **19**: 576–585.
- Krähenbühl S (1996) Carnitine metabolism in chronic liver disease. *Life Sci* **59**: 1579–1599.
- LaRusso NF, Hoffman NE, Korman MG, Hofmann AF, Cowen AE (1978) Determinants of fasting and postprandial serum bile acid levels in healthy man. *Am J Dig Dis* **23**: 385–391.
- Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, Yang M, Guan XY (2006) Clusterin plays an important role in hepatocellular carcinoma metastasis. *Oncogene* **25**: 1242–1250.
- Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP (2006) Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. *Proteomics* **6**: 2865–2873.
- Lee JY, Kim JY, Park GW, Cheon MH, Kwon KH, Ahn YH, Moon MH, Lee HJ, Paik YK, Yoo JS (2011) Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma. *Mol Cell Proteomics* **10**: M111 009290.
- Linkous AG, Yazlovitskaya EM, Hallahan DE (2010) Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. *J Natl Cancer Inst* **102**: 1398–1412.
- Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? *Hepatology* **47**: 82–89.
- Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. *Hepatology* **37**: 429–442.
- Lu Y, Liu J, Lin C, Wang H, Jiang Y, Wang J, Yang P, He F (2010) Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma. *BMC Gastroenterol* **10**: 115.
- Malaguarnera G, Bertino G, Vacante M, Malaguarnera M (2014) Hepatocellular carcinoma markers in the omics era: the glycomic analysis. *Hepatobiliary Surg Nutr* **3**: 407–409.
- Malaguarnera M (2012) Carnitine derivatives: clinical usefulness. *Curr Opin Gastroenterol* **28**: 166–176.
- Martínez-González D, Bonilla-Jaime H, Morales-Otal A, Henriksen SJ, Velázquez-Moctezuma J, Prospéro-García O (2004) Oleamide and anandamide effects on food intake and sexual behavior of rats. *Neurosci Lett* **364**: 1–6.
- Masuzaki R, Karp SJ, Omata M (2012) New serum markers of hepatocellular carcinoma. *Semin Oncol* **39**: 434–439.
- Matos JM, Witzmann FA, Cummings OW, Schmidt CM (2009) A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. *J Surg Res* **155**: 237–243.
- Mederacke I, Mencin A, Lefkowitz Jay H, Sartor RB, Dapito Dianne H, Rabadan R, Jang M-K, Pradere J-P, Caviglia Jorge M, Khiabani H, Schwabe Robert F, Friedman R, Bower M, Gwak G-Y, Bataller R, Adeyemi A (2012) Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4.
- Michitaka K, Hiraoka A, Kume M, Uehara T, Hidaka S, Ninomiya T, Hasebe A, Miyamoto Y, Ichiryu M, Tanihira T, Nakahara H, Ochi H, Tanabe A, Uesugi K, Tokumoto Y, Mashiba T, Abe M, Hiasa Y, Matsuura B, Onji M (2010) Amino acid imbalance in patients with chronic liver diseases. *Hepatology* **51**: 393–398.
- Morgan TR, Mandayam S, Jamal MM (2004) Alcohol and hepatocellular carcinoma. *Gastroenterology* **127**: S87–S96.
- Morita Y, Sakaguchi T, Ikegami K, Goto-Inoue N, Hayasaka T, Hang VT, Tanaka H, Harada T, Shibasaki Y, Suzuki A, Fukumoto K, Inaba K, Murakami M, Setou M, Konno H (2013) Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. *J Hepatol* **59**: 292–299.
- Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, Jeong AS, Cho SY, Kim SA, Song SY, Kim KS, Cho SW, Kim H, Paik YK (2009) Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. *Proteomics* **9**: 3989–3999.
- Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Zioli M, Seror O, Dhonneur G, Trinchet JC, Beaugrand M, Le Moyec L (2012a) Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. *Clin Cancer Res* **18**: 6714–6722.
- Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Zioli M, Seror O, Dhonneur G, Trinchet JC, Beaugrand M, Le Moyec L (2012b) Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. *Clin Cancer Res* **18**: 6714–6722.
- Saito Y, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K, Nakatsura T (2010) Identification of β 2-microglobulin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis. *Oncol Rep* **23**: 1325–1330.
- Neale G, Lewis B, Weaver V, Panveliwala D (1971) Serum bile acids in liver disease. *Gut* **12**: 145–152.
- Nesvizhskii AI (2007) Protein identification by tandem mass spectrometry and sequence database searching. *Methods Mol Biol* **367**: 87–119.
- Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans RO, Bakker SJ (2009) Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. *Atherosclerosis* **207**: 534–540.
- Paradis V, Degos F, Dargère D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P (2005) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. *Hepatology* **41**: 40–47.
- Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR (2011) Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. *Cancer Res* **71**: 6590–6600.
- Ponz De Leon M, Murphy GM, Dowling RH (1978) Physiological factors influencing serum bile acid levels. *Gut* **19**: 32–39.
- Regimbeau JM, Colombat M, Mognot P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J (2004) Obesity and diabetes as a risk factor for hepatocellular carcinoma. *Liver Transpl* **10**: S69–S73.
- Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR, Zhao Y, Wang J, Di Poto C, Cheema AK, Tadesse MG, Goldman R, Shetty K (2012) Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. *Anal Chim Acta* **743**: 90–100.
- Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajang S, Hainaut P, Marrero JA, Beretta L (2012) Identification of osteopontin as

- a novel marker for early hepatocellular carcinoma. *Hepatology* **55**: 483–490.
- Shariff MI, Gomaa AI, Cox IJ, Patel M, Williams HR, Crossey MM, Thillainayagam AV, Thomas HC, Waked I, Khan SA, Taylor-Robinson SD (2011) Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. *J Proteome Res* **10**: 1828–1836.
- Shariff MI, Ladep NG, Cox IJ, Williams HR, Okeke E, Malu A, Thillainayagam AV, Crossey MM, Khan SA, Thomas HC, Taylor-Robinson SD (2010) Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. *J Proteome Res* **9**: 1096–1103.
- Shen Y, Jacobs JM, Camp 2nd DG, Fang R, Moore RJ, Smith RD, Xiao W, Davis RW, Tompkins RG (2004) Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. *Anal Chem* **76**: 1134–1144.
- Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, Dwek R, Block TM (2003) A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. *Proteomics* **3**: 601–609.
- Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM (2010a) Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (< or = 2 cm). *J Proteome Res* **9**: 1923–1930.
- Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H, Qiao Y, Jia W, Bi X, Lu N, Liu S, Qian X, Zhao X (2008) Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. *J Proteome Res* **7**: 3847–3859.
- Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y, Sun L (2010b) Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. *Int J Mol Sci* **11**: 1423–1433.
- Taylor LA, Arends J, Hodina AK, Unger C, Massing U (2007) Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. *Lipids Health Dis* **6**: 17.
- Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Matak C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab* **10**: 167–177.
- Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov* **7**: 678–693.
- Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, Chen Y, Xu J, Zheng S, Li L (2012) Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. *J Proteome Res* **11**: 1217–1227.
- Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Martin A, Beaugrand M, Johnson PJ (2006) Preclinical and post-treatment changes in the HCC-associated serum proteome. *Br J Cancer* **95**: 1379–1383.
- Wei S, Suryani Y, Gowda GA, Skill N, Maluccio M, Raftery D (2012) Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling. *Metabolites* **2**: 701–716.
- Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X (2009) Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. *Anal Chim Acta* **648**: 98–104.
- Wu W, Li J, Liu Y, Zhang C, Meng X, Zhou Z (2012) Comparative proteomic studies of serum from patients with hepatocellular carcinoma. *J Invest Surg* **25**: 37–42.
- Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, Di Poto C, Wang J, Goerlitz D, Luo Y, Cheema AK, Sarhan N, Soliman H, Tadesse MG, Ziada DH, Resson HW (2012) LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. *J Proteome Res* **11**: 5914–5923.
- Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, Shen X (2008) A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. *Rapid communications in mass spectrometry: RCM* **22**: 3061–3068.
- Yang MH, Tyan YC, Jong SB, Huang YF, Liao PC, Wang MC (2007a) Identification of human hepatocellular carcinoma-related proteins by proteomic approaches. *Anal Bioanal Chem* **388**: 637–643.
- Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F (2007b) Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. *J Proteome Res* **6**: 2605–2614.
- Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, Lu X, Yang S, Gu J, Xu G (2009) A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. *Mol Biosyst* **5**: 868–876.
- Zhang A, Sun H, Yan G, Han Y, Ye Y, Wang X (2013) Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. *Clin Chim Acta* **418**: 86–90.
- Zhao Y, Jia W, Sun W, Jin W, Guo L, Wei J, Ying W, Zhang Y, Xie Y, Jiang Y, He F, Qian X (2010) Combination of improved (18)O incorporation and multiple reaction monitoring: a universal strategy for absolute quantitative verification of serum candidate biomarkers of liver cancer. *J Proteome Res* **9**: 3319–3327.
- Zhou L, Ding L, Yin P, Lu X, Wang X, Niu J, Gao P, Xu G (2012a) Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry. *J Proteome Res* **11**: 5433–5442.
- Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, Lu X, Zhang Y, Lin X, Xu G (2012b) Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. *Anal Bioanal Chem* **403**: 203–213.